このページの翻訳は実験的なもので、現在開発中です。お待ちしております

SQI Diagnostics マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Andrew Morris

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	2.8yrs
CEOの所有権	n/a
経営陣の平均在職期間	4.3yrs
取締役会の平均在任期間	11.9yrs

経営陣の近況

Recent updates

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Dec 22

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Nov 17

CEO報酬分析

SQI Diagnostics の収益と比較して、Andrew Morris の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2023	n/a	n/a	-CA$19m
Dec 31 2022	n/a	n/a	-CA$18m
Sep 30 2022	CA$543k	CA$400k	-CA$19m
Jun 30 2022	n/a	n/a	-CA$13m
Mar 31 2022	n/a	n/a	-CA$9m
Dec 31 2021	n/a	n/a	-CA$10m
Sep 30 2021	CA$265k	CA$265k	-CA$11m
Jun 30 2021	n/a	n/a	-CA$11m
Mar 31 2021	n/a	n/a	-CA$12m
Dec 31 2020	n/a	n/a	-CA$10m
Sep 30 2020	CA$265k	CA$265k	-CA$9m
Jun 30 2020	n/a	n/a	-CA$9m
Mar 31 2020	n/a	n/a	-CA$9m
Dec 31 2019	n/a	n/a	-CA$8m
Sep 30 2019	CA$348k	CA$300k	-CA$8m
Jun 30 2019	n/a	n/a	-CA$7m
Mar 31 2019	n/a	n/a	-CA$7m
Dec 31 2018	n/a	n/a	-CA$7m
Sep 30 2018	CA$330k	CA$300k	-CA$7m
Jun 30 2018	n/a	n/a	-CA$7m
Mar 31 2018	n/a	n/a	-CA$7m
Dec 31 2017	n/a	n/a	-CA$6m
Sep 30 2017	CA$300k	CA$300k	-CA$6m

報酬と市場: Andrewの総報酬がCanadian市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Andrewの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Andrew Morris (58 yo)

2.8yrs

在職期間

CA$543,040

報酬

Mr. Andrew Morris serves as the Chief Executive Officer, Chief Financial Officer, President & Director of Rose Diagnostics Inc. Mr. Morris is Chief Executive Officer of SQI Diagnostics Inc. from September...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Andrew Morris	Advisor to the Board & CEO	2.8yrs	CA$543.04k	データなし
Morlan Reddock	CFO & VP of Administration	4.3yrs	CA$200.00k	データなし
Eric Brouwer	Chief Scientific Officer & Advisor to the Board	6.8yrs	CA$350.00k	データなし
Peter Lea	Founder	25.5yrs	データなし	データなし
Tim McGough	Chief Commercial Officer	1.8yrs	データなし	データなし

4.3yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: SQDの経営陣は経験豊富であると考えられます ( 3.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Gerald Connor	Independent Director	9.3yrs	データなし	24.46% CA$ 1.5m
Yehuda Shoenfeld	Chairman of Scientific Advisory Board	14.5yrs	データなし	データなし
Claude Ricks	Independent Director	17.2yrs	CA$4.00k	データなし
Eric Zwisler	Independent Director	6.1yrs	データなし	データなし

11.9yrs

平均在職期間

71yo

平均年齢

経験豊富なボード: SQD.Hの取締役会は経験豊富で経験豊富です ( 11.9年の平均在任期間)。

SQI Diagnostics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Insufficient new directors

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Independent Director recently sold CA$56k worth of stock

Recent updates

SQI Diagnostics Inc. Ordinary Shares to Be Deleted from OTC Equity

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)

Insufficient new directors

First quarter 2023 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2022)

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Full year 2022 earnings released: CA$0.048 loss per share (vs CA$0.031 loss in FY 2021)

SQI Installs Two Rali-Dx Systems in Toronto Hospitals to Fight the Growing Respiratory Health Crisis in Emergency Departments

SQI Diagnostics Inc. announced that it expects to receive CAD 1 million in funding

SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario

SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test

Third quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.002 loss in 3Q 2021)

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics (CVE:SQD) Has Debt But No Earnings; Should You Worry?

New York State Approves SQI Diagnostics' Exact Covid-19 Antibody Assay

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics Systems Inc. signed a definitive agreement to acquire all of the assets underlying Precision Biomonitoring Inc businesses from Precision Biomonitoring Inc. for CAD 6.825 million

SQI Diagnostics Inc. announced that it expects to receive CAD 6 million in funding

Third quarter 2021 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2020)

Is SQI Diagnostics (CVE:SQD) Weighed On By Its Debt Load?

FDA Stops Emergency Use Authorization Review of SQI Diagnostics Inc. RALI-Dx IL-6 Severity Triage Test for Covid-19 Patients

CEO & Director Robert Chioini has left the company

Second quarter 2021 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 2Q 2020)

Health Check: How Prudently Does SQI Diagnostics (CVE:SQD) Use Debt?

Independent Director recently sold CA$56k worth of stock

Are Insiders Buying SQI Diagnostics Inc. (CVE:SQD) Stock?

First quarter 2021 earnings released: CA$0.012 loss per share (vs CA$0.009 loss in 1Q 2020)

Director exercised options to buy CA$705k worth of stock.

Director recently bought CA$660k worth of stock

New 90-day high: CA$0.40

SQI Diagnostics Inc., Annual General Meeting, Mar 31, 2021

Full year 2020 earnings released: CA$0.032 loss per share (vs CA$0.045 loss in FY 2019)

Is SQI Diagnostics Inc. (CVE:SQD) Popular Amongst Insiders?

SQI Diagnostics Announces Patient Enrollment Begins for its COVID-19 HOME Antibody Test Clinical Study

New 90-day high: CA$0.28

Independent Director exercised options to buy CA$1.7m worth of stock.

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Sqi Diagnostics Inc. Updates Clinical Progress on Novel Covid-19 Tests Under Development for U.S. Fda Regulatory Submission

Third quarter earnings released

SQI Diagnostics Inc. Announces Executive Changes

New 90-day high - CA$0.21

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24